Chronic Refractory Cough Market Forecast
As per DelveInsight estimates, the total Chronic cough prevalent population in the 7 MM was estimated to be 84,854,266 in 2020; and for Chronic refractory cough, the prevalence was recorded to be 17,600,264 in 2020.
The Chronic Refractory Cough market size in the seven major markets is expected to show a positive growth at a CAGR of 6.57% during the study period 2018–2030.
The Chronic Refractory Cough market is dominated by off-label therapies. Currently, Chronic Refractory Cough treatment involves the use of various over-the-counter drugs and therapies.
Owing to the positive outcomes of the upcoming products by key companies such as Merck, NeRRe Therapeutics Ltd, Bayer Pharmaceuticals, Shionogi Inc., and Bellus Health, the Chronic Refractory Cough Market will create a significant positive shift in the market size.
For more detailed information, visit: Chronic Refractory Cough Market Forecast